Cholesterol

Bringing thirteen compounds into clinical testing in just over three years is no mean achievement for a company, which has just barely crested the $1 billion mark in market capitalization.

The accomplisher of this unique achievement is Exelixis.

The company experienced a setback with its experimental cancer drug, XL999 last year as it had to halt enrollment of new patients in its phase II trial with XL999 after a safety monitoring board noticed an elevated level of serious cardiovascular adverse events.

On Tuesday, the FDA allowed Exelixis to resume testing of XL999, which had been kept on partial hold since last December.

The company also submitted an application to the FDA seeking approval to commence human clinical trials with XL765, a drug candidate for non-small cell lung cancer.

After years of touting the effectiveness of Dexanabinol in treating Traumatic Brain Injury or TBI, drug developer Pharmos in December 2004, announced that Dexanabinol was not found to be materially effective in Phase III testing.

Pharmos almost got crushed with its stock price plummeting 66%, back then.

The field of biotechnology is fraught with risk and disappointment and biotech...

Read more...